Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Heart Valve Replacement

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age19+
SponsorAsan Medical Center

About this trial

This trial is a multinational, multicenter, randomized, open-label, active-controlled clinical trial comparing the safety of aspirin versus vitamin K antagonists (warfarin) as oral antithrombotic therapy during the initial 6 months following tissue valve replacement (aortic or mitral).

Eligibility criteria

Qualifiers

Aged ≥ 19 years with successful surgical bioprosthetic valve replacement

Bioprosthetic heart valve in aortic or mitral valve positions, for a day postoperatively

The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

Disqualifiers

Mechanical valve in any heart valve position

Previous hemorrhagic stroke within the last 3 months

Clinically overt stroke within the last 3 months

Current need for anticoagulation (i.e. atrial fibrillation, deep vein thrombosis)

Trial design

Treatments tested in this trial

  • Aspirin
  • Vitamin K antagonist(warfarin)

Treatment groups

1,058 Participants
are divided into 2 treatment groups

Sponsors and collaborators